Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Preclinical data from the University of Pennsylvania's Gene Therapy Program highlights the efficacy of a single injection of AAVhu68 delivering the GALC gene in animal models of Krabbe disease. The study revealed normalization of GALC enzyme activity, improved nerve conduction, and enhanced brain health in treated mice and dogs. The data suggests PBKR03 could be a major breakthrough for infantile Krabbe disease, aiming for IND submission later this year. The findings indicate significant potential for this gene therapy to restore myelination and nerve functions, ultimately increasing survival rates.
Passage Bio (NASDAQ: PASG) has expanded its collaboration with the Gene Therapy Program (GTP) at the University of Pennsylvania. This includes licensing an additional five programs, extending the collaboration to 2025, and committing $5 million annually for research funding. The agreement grants Passage exclusive rights to technologies developed during this partnership for their gene therapy products. This move is expected to enhance Passage's pipeline and expertise in creating transformative therapies for rare CNS disorders.